Problem of detection and pharmacological correction of anxious and depressive disorders in patients with type 2 diabetes mellitus


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Depression and anxiety are frequent companions of chronic somatic diseases. The most acute question is about the pharmacotherapy of these conditions in type 2 diabetes mellitus (DM2), when, due to the similarity of the clinical symptoms and manifestations of anxious disorders, they are difficult to differentiate, and treatment compliance is violated. The presence of anxiety and depressive disorders contributes to the progression of the underlying disease and its complications. Objective. Evaluation of the incidence of anxiety and depressive disorders in DM1 and DM2 patients during planned hospitalization. Methods. Filling EQ5D5L and HADS questionnaires by patients (DM1 - 50 patients, DM2 - 47 patients) of School of Diabetes. Results. Subclinical and clear signs of depression and/or anxiety were detected in all DM2 patients, while these indicators were within the normal range in DM1 patients. DM2 patients assessed their own quality of life significantly lower than DM1 patients. Conclusion. DM2 patients have a high incidence of anxious and depressive disorders identified during screening. The timely detection and pharmacological support of such patients with such disorders can help to improve their quality of life and the effectiveness of glucose-lowering therapy due to their greater adherence to treatment.

Full Text

Restricted Access

About the authors

Yu. A Sorokina

Nizhny Novgorod State Medical Academy

A. V Zanozin

Narcological Hospital, Nizhny Novgorod

O. V Zanozina

Nizhny Novgorod State Medical Academy; Nizhny Novgorod Regional Clinical Hospital (NNRCH) n.a. Semashko

Email: zwx2@mail.ru
MD, Professor of the Department of Hospital Therapy; Head of the Department of Endocrinology

G. P Runov

Nizhny Novgorod State Medical Academy; Nizhny Novgorod Regional Clinical Hospital (NNRCH) n.a. Semashko

References

  1. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 8-й выпуск. М., 2017.
  2. Аметов А.С., Курочкин И.О., Зубков А.А. Сахарный диабет и сердечно-сосудистые заболевания. РМЖ. 2014;13:49-54.
  3. Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения. 2-е изд., доп. и перераб. М.: ГЭОТАР-Медиа, 2014. 1032 с.
  4. Андрюшенко А.В., Дробижев М.Ю., Добровольский А.В. Сравнительная оценка шкал CES-D, BDI и HADS(d) в диагностике депрессий в общемедицинской практике. Журнал неврологии и психиатрии. 2003;5:11-
  5. Зеленин К.А. Тревожные расстройства у больных сахарным диабетом 2 типа. Диса канд. мед. наук (автореферат). М., 2011. 19 с.
  6. Недосугова Л.В. Окислительный стресс при сахарном диабете типа 2 и возможности его медикаментозной коррекции. Дисс. докт. мед. наук. М., 2006. 375 с.
  7. Носиков В.В., Серегин Ю.А. Молекулярная генетика сахарного диабета типа 1: достижения и перспективы. Молекулярная биология. 2008;42(5):867-79.
  8. Шальнова С.А., Евстифеева С.Е., Деев А.Д. и др. Распространенность тревоги и депрессии в различных регионах Российской Федерации и ее ассоциации с социально-демографическими факторами (по данным исследования ЭССЕ-РФ). Терапевтический архив. 2014;12:53-60.
  9. Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: МедиаСфера, 2000. 312 с.
  10. Сорокина Ю.А., Занозин А.В., Занозина О.В. Необходимость и возможность комбинации метформина и сертралина у больных сахарным диабетом 2-го типа. Медицинский альманах. 2017;6(51):122-25.
  11. Abe K., Kuo L., Zukowska Z. Neuropeptide Y. is a mediator of chronic vascular and metabolic maladaptations to stress and hypernutrition. Experimental Biology and Medicine. 2010;235(10):1179-84. Doi: 10.1258/ ebm.2010.009136.
  12. Amirdjanova V.N., Erdes S.F. Validation of general questionnaire EuroQol-5D (EQ-5D) Russian version. Rheumatology Science and Practice. 2007;45(3):69-76. doi: 10.14412/1995-4484-2007-69.
  13. Beck A.T., Ward C.H., Mendelson M., et. al. An Inventory for Measuring Depression. Archives of general psychiatry. 1961;4(6):561-71.
  14. Gonzalez J.S., Safren S.A., Cagliero E. et al. Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diabetes Care. 2007;30(9):2222-27.
  15. Forsell Y., Jorm A.F., Winblad B. Association of age, sex, cognitive dysfunction, and disability with major depressive symptoms in an elderly sample. Am J. Psychiatry. 1994;151(11):1600-604
  16. Hamilton M. A rating scale for depression. J. Neurol Neurosurg Psychiatry. 1960;23:56-62.
  17. Holt R.I., Katon W.J. Dialogue on Diabetes and Depression: Dealing with the double burden of co-morbidity. J. Affect Disord. 2012;142:1-3. doi: 10.1016/S0165-0327(12)00632-5.
  18. Bogner H.R., Morales K.H., de Vries H.F., et al. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: a randomized controlled trial. Ann Fam Med. 2012;10:15-22. doi: 10.1370/afm.1344.
  19. Kaye W.H., Strober M. Neurobiology of eating disorders. Neurobiological foundation of mental illness. New York: Oxford University Press, 1999. Р. 891-906.
  20. Kaye W.H., Ann N.Y. Persistent alterations in behavior and serotonin activity after recovery from anorexia and bulimia nervosa. AcadSci. 1997;817:162-78.
  21. Pedragosa-Badia X., Stichel J., Beck-Sickinger A.G. Neuropeptide Y receptors: how to get subtype selectivity. Frontiers in Endocrinology 2013;4:(5):1 3. doi: 10.3389/fendo.2013.00005
  22. Waldfogel J.M., Nesbit S.A., Dy S.M., et. al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. Neurology. 2017;88(20):1958-67. doi: 10.1212/WNL.0000000000003882
  23. Zhao Q., Wu X., Yan S., et al. The antidepressantlike effects of pioglitazone in a chronic mild stress mouse model are associated with PPARy-mediated alteration of microglial activation phenotypes. J Neuroinflammation. 2016;13:259. Doi:10.1186/ s12974-016-0728-y
  24. World Health Organization. Quality of lifegroup. What is it Quality of life? Wid. Hth. Forum. 1996;1:29.
  25. Zigmond A.S., Snaith R.P The Hospital Anxiety and Depression scale. Acta Psychiatr Scand. 1983;67:361-70.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media